Celldex Therapeutics, Inc.

NASDAQ:CLDX

Biotechnology

Healthcare
$27.96 +0.47%

+$0.16 today

Market cap
$2.20B
Beta
0.93
P/E (TTM)
-7.8
EPS (TTM)
-$4.26
52W Low $19.52High $35.79

Volume 0.75M

Average 0.94M

Returns on capital

Celldex Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-49.1%

avg -44.6%

ROIC

-53.9%

avg -41.8%

ROA

-44.4%

avg -37.0%

Analysis

ROA is currently the strongest return metric at -44.4% versus its period average of -37.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Anthony S. Marucci

Founder, President, Chief Executive Officer & DirectorUSD 1.34M64375.00K0.56%

Tibor Keler

Founder, Chief Scientific Officer & Executive Vice PresidentUSD 867.16K67115.00K0.17%

Elizabeth Crowley

Chief Product Development Officer & Senior Vice PresidentUSD 744.06K54100.00K0.15%

Sam Martin

Senior Vice President, Chief Financial Officer, Secretary & TreasurerUSD 739.66K55——

Margo Heath-Chiozzi

Senior Vice President of Regulatory AffairsUSD 719.48K6995.00K0.14%

Diane C. Young

Senior Vice President & Chief Medical OfficerUSD 696.45K6957.00K0.09%

Freddy A. Jimenez

Senior Vice President & General CounselUSD 579.7K5793.00K0.14%

Ronald A. Pepin

Chief Business Officer & Senior Vice PresidentUSD 441.84K70——

Joseph Schlessinger

Co-Founder & Member of Scientific Advisory Board—81——

Sarah Cavanaugh

Senior Vice President of Corporate Affairs & Administration—5195.00K0.14%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 25, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

1

$121,209.77

Net Transaction Value

−$121,209.77

Net selling

Most Active

Jimenez Freddy A.

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Dec 4, 25

Jimenez Freddy A.

Direct

Sell$121.2K

Summary

Insiders reported 0 buys worth $0.00 and 1 sells worth $121,209.77 over the last 12 months. That adds up to net selling of $121,209.77. Jimenez Freddy A. was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A3 analysts
RevenueN/AN/A-14.0%
+262.4% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Recent growth has been strongest in Revenue at -14.0% over three years. Forward estimates point to Revenue at +262.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Celldex Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about CLDX's management, answered from reported figures.

Who manages CLDX?

Celldex Therapeutics, Inc. (CLDX) lists 10 active executives. The top listed executive is Diane C. Young, Senior Vice President & Chief Medical Officer.

Are CLDX insiders buying or selling?

Recent insider activity shows net buying of $136.44M.